EA201791525A3 - Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w - Google Patents
Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-wInfo
- Publication number
- EA201791525A3 EA201791525A3 EA201791525A EA201791525A EA201791525A3 EA 201791525 A3 EA201791525 A3 EA 201791525A3 EA 201791525 A EA201791525 A EA 201791525A EA 201791525 A EA201791525 A EA 201791525A EA 201791525 A3 EA201791525 A3 EA 201791525A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- retrovirus
- expression
- treatment
- remielinization
- blocade
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001681 protective effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 3
- 241000896769 Multiple sclerosis associated retrovirus Species 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 101710094648 Coat protein Proteins 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 102000006386 Myelin Proteins Human genes 0.000 abstract 1
- 108010083674 Myelin Proteins Proteins 0.000 abstract 1
- 101710141454 Nucleoprotein Proteins 0.000 abstract 1
- 101710083689 Probable capsid protein Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000005012 myelin Anatomy 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к новым соединениям и композициям для профилактики и/или лечения вновь выявленного повреждающего механизма, блокирующего способность восстановления эндогенного миелина зрелой нервной системы (HC) при заболеваниях, связанных с экспрессией белка оболочки (ENV, envelope protein) HERV-W (human endogenous retrovirus, эндогенный ретровирус типа W человека), в частности его подтипа MSRV (multiple sclerosis-associated retrovirus, ретровирус, ассоциированный с рассеянным склерозом).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261708779P | 2012-10-02 | 2012-10-02 | |
US201261746792P | 2012-12-28 | 2012-12-28 |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201791525A2 EA201791525A2 (ru) | 2018-07-31 |
EA201791525A3 true EA201791525A3 (ru) | 2018-12-28 |
EA037253B1 EA037253B1 (ru) | 2021-02-26 |
Family
ID=49274655
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590678A EA028245B1 (ru) | 2012-10-02 | 2013-10-01 | Композиция для профилактики и/или лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w |
EA201791525A EA037253B1 (ru) | 2012-10-02 | 2013-10-01 | Применение лиганда анти-herv-w env для профилактики и/или лечения прогрессирующего рассеянного склероза и способ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590678A EA028245B1 (ru) | 2012-10-02 | 2013-10-01 | Композиция для профилактики и/или лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w |
Country Status (31)
Country | Link |
---|---|
US (2) | US9840550B2 (ru) |
EP (2) | EP3447070B9 (ru) |
JP (2) | JP6379331B2 (ru) |
KR (1) | KR102098033B1 (ru) |
CN (2) | CN104684927B (ru) |
AU (2) | AU2013326552B2 (ru) |
BR (1) | BR112015007150A8 (ru) |
CA (1) | CA2882781C (ru) |
CY (2) | CY1121237T1 (ru) |
DK (2) | DK2904009T3 (ru) |
EA (2) | EA028245B1 (ru) |
EC (1) | ECSP15014925A (ru) |
ES (2) | ES2878248T3 (ru) |
HK (1) | HK1221399A1 (ru) |
HR (2) | HRP20190274T1 (ru) |
HU (2) | HUE054051T2 (ru) |
IL (3) | IL237474A0 (ru) |
IN (1) | IN2015DN02397A (ru) |
LT (2) | LT2904009T (ru) |
MX (2) | MX366846B (ru) |
MY (1) | MY172209A (ru) |
PL (2) | PL2904009T3 (ru) |
PT (2) | PT2904009T (ru) |
RS (2) | RS61794B1 (ru) |
RU (1) | RU2636355C2 (ru) |
SA (1) | SA515360207B1 (ru) |
SG (1) | SG11201501274VA (ru) |
SI (2) | SI3447070T1 (ru) |
UA (1) | UA119032C2 (ru) |
WO (1) | WO2014053489A1 (ru) |
ZA (1) | ZA201501491B (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2949342A1 (en) * | 2014-05-28 | 2015-12-02 | Geneuro SA | Antiretroviral drug targeting human endogenous retrovirus |
EP3351265A1 (en) * | 2017-01-20 | 2018-07-25 | Geneuro SA | Anti-herv-k envelope antibody and uses thereof |
JP7122002B2 (ja) | 2017-03-01 | 2022-08-19 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
JP7317377B2 (ja) * | 2018-09-01 | 2023-07-31 | 国立大学法人北海道大学 | ストレス負荷が関与する疾患を予防及び/又は治療するための医薬 |
EP4025303A1 (en) * | 2019-09-04 | 2022-07-13 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Herv inhibitors for use in treating tauopathies |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
IL151868A0 (en) * | 2000-03-21 | 2003-04-10 | Ms Res As | An infective endogenous retrovirus and its association with demyelinating diseases and other diseases |
RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
FR2865403B1 (fr) * | 2004-01-23 | 2009-06-12 | Biomerieux Sa | Composition pour le traitement d'une pathologie associee a la msrv/herv-w |
US20090233888A1 (en) * | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
JP2009531304A (ja) * | 2006-02-28 | 2009-09-03 | エラン ファーマシューティカルズ,インコーポレイテッド | α−4阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法 |
WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
CA2705435A1 (en) * | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
MX2010014319A (es) * | 2008-07-08 | 2011-05-19 | Geneuro Sa | Uso terapeutico de ligando especifico en enfermedades asociadas con msrv. |
JP2012505257A (ja) * | 2008-10-13 | 2012-03-01 | バイオヴィスタ,インコーポレイテッド | 多発性硬化症治療のための組成物および方法 |
WO2010148323A2 (en) * | 2009-06-18 | 2010-12-23 | Whittemore Peterson Institute For Neuro-Immune Disease | Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus |
ME02317B (me) * | 2010-02-12 | 2016-06-20 | Biogen Ma Inc | Neuroprotekcija kod demijelinizacijskih bolesti |
-
2013
- 2013-01-10 UA UAA201504292A patent/UA119032C2/uk unknown
- 2013-10-01 RS RS20210555A patent/RS61794B1/sr unknown
- 2013-10-01 AU AU2013326552A patent/AU2013326552B2/en active Active
- 2013-10-01 DK DK13770926.7T patent/DK2904009T3/en active
- 2013-10-01 MY MYPI2015700643A patent/MY172209A/en unknown
- 2013-10-01 CA CA2882781A patent/CA2882781C/en active Active
- 2013-10-01 PL PL13770926T patent/PL2904009T3/pl unknown
- 2013-10-01 US US14/429,199 patent/US9840550B2/en active Active
- 2013-10-01 IN IN2397DEN2015 patent/IN2015DN02397A/en unknown
- 2013-10-01 ES ES18198309T patent/ES2878248T3/es active Active
- 2013-10-01 HU HUE18198309A patent/HUE054051T2/hu unknown
- 2013-10-01 DK DK18198309.9T patent/DK3447070T3/da active
- 2013-10-01 EP EP18198309.9A patent/EP3447070B9/en active Active
- 2013-10-01 PT PT13770926T patent/PT2904009T/pt unknown
- 2013-10-01 CN CN201380051713.4A patent/CN104684927B/zh active Active
- 2013-10-01 EA EA201590678A patent/EA028245B1/ru unknown
- 2013-10-01 SG SG11201501274VA patent/SG11201501274VA/en unknown
- 2013-10-01 MX MX2015003572A patent/MX366846B/es active IP Right Grant
- 2013-10-01 BR BR112015007150A patent/BR112015007150A8/pt not_active Application Discontinuation
- 2013-10-01 SI SI201331879T patent/SI3447070T1/sl unknown
- 2013-10-01 JP JP2015533633A patent/JP6379331B2/ja active Active
- 2013-10-01 PT PT181983099T patent/PT3447070T/pt unknown
- 2013-10-01 EA EA201791525A patent/EA037253B1/ru unknown
- 2013-10-01 LT LTEP13770926.7T patent/LT2904009T/lt unknown
- 2013-10-01 RS RS20190185A patent/RS58320B1/sr unknown
- 2013-10-01 RU RU2015116149A patent/RU2636355C2/ru active
- 2013-10-01 ES ES13770926T patent/ES2710748T3/es active Active
- 2013-10-01 LT LTEP18198309.9T patent/LT3447070T/lt unknown
- 2013-10-01 HU HUE13770926A patent/HUE043419T2/hu unknown
- 2013-10-01 PL PL18198309T patent/PL3447070T3/pl unknown
- 2013-10-01 KR KR1020157011152A patent/KR102098033B1/ko active IP Right Grant
- 2013-10-01 SI SI201331348T patent/SI2904009T1/sl unknown
- 2013-10-01 EP EP13770926.7A patent/EP2904009B1/en active Active
- 2013-10-01 WO PCT/EP2013/070452 patent/WO2014053489A1/en active Application Filing
- 2013-10-01 CN CN201610152679.5A patent/CN105709224B/zh active Active
-
2015
- 2015-02-26 IL IL237474A patent/IL237474A0/en unknown
- 2015-03-04 ZA ZA2015/01491A patent/ZA201501491B/en unknown
- 2015-03-19 MX MX2019008916A patent/MX2019008916A/es unknown
- 2015-03-30 SA SA515360207A patent/SA515360207B1/ar unknown
- 2015-04-17 EC ECIEPI201514925A patent/ECSP15014925A/es unknown
-
2016
- 2016-08-01 HK HK16109172.3A patent/HK1221399A1/zh unknown
-
2017
- 2017-11-07 JP JP2017214696A patent/JP6538138B2/ja active Active
- 2017-11-14 US US15/812,745 patent/US10752675B2/en active Active
-
2018
- 2018-08-17 AU AU2018217328A patent/AU2018217328B2/en active Active
-
2019
- 2019-01-21 IL IL264382A patent/IL264382B/en active IP Right Grant
- 2019-02-07 CY CY20191100169T patent/CY1121237T1/el unknown
- 2019-02-11 HR HRP20190274TT patent/HRP20190274T1/hr unknown
-
2020
- 2020-04-19 IL IL274047A patent/IL274047B/en active IP Right Grant
-
2021
- 2021-05-11 CY CY20211100400T patent/CY1124378T1/el unknown
- 2021-05-14 HR HRP20210779TT patent/HRP20210779T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201890201A1 (ru) | Антибактериальные соединения | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
EA201491548A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
MX2015016741A (es) | Inhibidores de pi3 cinasa delta y gama selectivos duales. | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
PH12017500304A1 (en) | Vaccine compositions against dengue virus diseases | |
EA201500851A1 (ru) | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
PH12017500615B1 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
EA201791525A2 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
EA202191515A1 (ru) | Фармацевтическая композиция, содержащая апиксабан | |
UY34896A (es) | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
CR20160353A (es) | Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
EA201491581A1 (ru) | Везикулярные композиции |